Table 2. Comorbidities and treatments of rheumatoid arthritis patients.
| Variables | n | % | n | % | n | % | p |
| Comorbidity | |||||||
| Without comorbidity | 18 | 36 | 13 | 24,5 | 31 | 30,1 | 0.205* |
| Hypertension | 19 | 38 | 25 | 47,2 | 44 | 42,7 | |
| Diabetes mellitus | 5 | 10 | 9 | 17 | 14 | 13,5 | |
| Chronic pulmonary disease | 6 | 12 | 10 | 18,9 | 16 | 15,5 | |
| Cerebrovascular disease | 1 | 2 | 2 | 3,8 | 3 | 2,9 | |
| Ischemic heart disease | 2 | 4 | 7 | 13,2 | 9 | 8,9 | |
| Thyroid disease | 3 | 6 | 4 | 7,5 | 7 | 6,8 | |
| Drug therapy | |||||||
| Parenteral route of administration | 10 | 20 | 4 | 7,5 | 14 | 13,5 | 0.059* |
| Methotrexate | 22 | 44 | 32 | 60,4 | 54 | 52,4 | |
| Hydroxychloroquine | 20 | 40 | 20 | 37,7 | 40 | 38,9 | |
| Prednisolone | 22 | 44 | 32 | 60,4 | 54 | 52,4 | |
| Biologics | 5 | 10 | 2 | 3,8 | 7 | 6,8 | |
| Methotrexate sc | 5 | 10 | 2 | 3,8 | 7 | 6,8 | |
| Leflunomide | 8 | 16 | 11 | 20,7 | 19 | 18,5 | |
| Sulfasalazine | 8 | 16 | 6 | 11,4 | 14 | 13,5 | |
| Tofacitinib | 1 | 2 | 1 | 1,9 | 2 | 1,9 | |
| * Chi-square test; P<0.05 was accepted statistically significant. | |||||||